• Applied Protocols with SU 5402: Cancer Biology & iPSC Models

  2026-05-27

  SU 5402 from APExBIO empowers researchers to dissect receptor tyrosine kinase signaling in cancer biology and advanced neuronal models. This article details workflow enhancements, troubleshooting insights, and cross-domain applications, with special attention to integrating SU 5402 into iPSC-derived sensory neuron assays.

• Phosbind Acrylamide: Enabling Quantitative Phosphorylation A

  2026-05-26

  Explore how Phosbind Acrylamide empowers precise protein phosphorylation analysis in dynamic signaling pathways—without phospho-specific antibodies. This article uniquely bridges mechanistic insights with advanced protocol optimization for challenging experimental contexts.

• Phosbind Biotin: Dinuclear Metal Complex for Phosphorylation

  2026-05-26

  Phosbind Biotin streamlines sequence-independent detection of phosphorylated proteins in Western Blot, transforming post-translational modification analysis. Its dinuclear metal complex phosphate binding mechanism offers superior sensitivity and workflow flexibility, making it ideal for high-impact studies in signal transduction and plant stress biology.

• Parathyroid Hormone (1-34) (Human): Advanced Experimental St

  2026-05-25

  Explore the advanced experimental applications of Parathyroid hormone (1-34) (human) in bone metabolism research and next-generation kidney disease modeling. This article delivers in-depth scientific insights and practical protocol guidance for leveraging this potent PTH (1-34) peptide fragment in translational studies.

• Rethinking FGFR1 Inhibition: PD 173074 in Diabetic Kidney Di

  2026-05-25

  This thought-leadership article explores the dual role of PD 173074 as a selective FGFR1/VEGFR2 inhibitor in cancer and chronic kidney disease. Integrating new mechanistic insights from FGF4-FGFR1 signaling in diabetic kidney disease (DKD), it offers translational researchers strategic guidance on leveraging PD 173074 for next-generation disease models, while critically assessing protocol design, competitive landscape, and future directions.

• FGFR1 as an Essential Regulator in Early Human Adipogenesis

  2026-05-24

  This study establishes fibroblast growth factor receptor 1 (FGFR1) as a critical determinant of early adipogenic events in human preadipocytes. By combining genetic and pharmacologic inhibition strategies, the research demonstrates FGFR1’s unique role in priming and promoting adipocyte formation, highlighting its potential as a therapeutic target in obesity interventions.

• PEDV Rewires Host IMPDH Pathway: Merimepodib Suppresses Repl

  2026-05-23

  The reference study uncovers how porcine epidemic diarrhea virus (PEDV) reprograms host guanine nucleotide biosynthesis via the IMPDH pathway to support its replication. Both genetic and pharmacological inhibition of IMPDH, especially with Merimepodib (VX-497), sharply reduce PEDV replication, highlighting IMPDH as a promising host-directed antiviral target for veterinary virology.

• Dissecting Drug Response Phenotypes with Advanced In Vitro M

  2026-05-22

  Schwartz's dissertation redefines in vitro drug evaluation in cancer biology by rigorously distinguishing relative viability from fractional viability when analyzing anti-cancer drug effects. This separation enables a more nuanced understanding of how drugs differentially impact cell proliferation and death, informing the development and interpretation of more predictive in vitro assays.

• Pentoxifylline (SKU C3816): Reliable PDE Inhibition in Cell

  2026-05-22

  This article addresses common laboratory challenges in cell viability, proliferation, and cytokine inhibition assays, demonstrating how Pentoxifylline (SKU C3816) serves as a dependable phosphodiesterase inhibitor for reproducible and data-driven results. By focusing on evidence-backed protocols and scenario-driven guidance, researchers can optimize assay reliability and comparability while leveraging APExBIO’s quality standards.

• CHI3L1-IN-5 (Z17): Mechanistic Leverage for Translational Ne

  2026-05-21

  Explore how CHI3L1-IN-5 (Compound Z17) empowers translational researchers by integrating mechanistic insights with workflow strategy to advance neuroinflammation and neurodegeneration research. This article synthesizes the latest structure-activity findings, translational protocols, and the evolving competitive landscape, offering actionable guidance and a visionary outlook for the deployment of selective CHI3L1 inhibitors in central nervous system (CNS) disease models.

• Cy3 Goat Anti-Rabbit IgG (H+L) Antibody: Protocol & QC Guide

  2026-05-21

  The Cy3 Goat Anti-Rabbit IgG (H+L) Antibody enables sensitive detection and signal amplification of rabbit primary antibodies in immunofluorescence, immunohistochemistry, and related workflows. It is best suited for applications requiring high specificity and fluorescent labeling. This product should not be used for diagnostic or clinical purposes, or where direct conjugation is needed.

• BGJ398 (NVP-BGJ398): Optimizing FGFR Signaling Workflows in

  2026-05-20

  BGJ398 (NVP-BGJ398) empowers researchers to dissect FGFR-driven pathways with precision, advancing both cancer and developmental biology research. This article provides actionable workflows, troubleshooting strategies, and integrates the latest reference findings to maximize experimental success using this selective FGFR inhibitor.

• Preserving Phosphorylation: Strategic Advances with Phosphat

  2026-05-20

  This article examines the mechanistic necessity and translational impact of robust phosphatase inhibition in phosphoprotein research, contextualized by new insights into autophagic flux and hepatic steatosis. It offers actionable guidance for optimizing protein phosphorylation preservation, highlights the capabilities of APExBIO's Phosphatase Inhibitor Cocktail 3, and provides a forward-looking perspective for researchers seeking reproducible, clinically relevant signaling data.

• LL-37 and Mimetics: Selective Antibiofilm Activity via Cryst

  2026-05-19

  This study investigates the antimicrobial and antibiofilm properties of the human peptide LL-37 and two truncated mimetics, KE-18 and KR-12, against major pathogens. It highlights the use of crystal violet staining to distinguish between biocidal and biofilm-preventive effects, offering insights for therapeutic development and assay design.

• Berberine Hydrochloride: Mechanistic Leverage in Translation

  2026-05-19

  This thought-leadership article explores the emerging translational landscape of Berberine hydrochloride, focusing on its role in gut-bone axis modulation, metabolic regulation, and osteoimmune homeostasis. Integrating recent mechanistic advances—including tuft cell expansion and AMPK activation—the discussion offers experimental parameters, strategic guidance, and a forward-looking perspective for researchers pursuing type 2 diabetes and osteoporosis models. The piece contextualizes APExBIO's Berberine hydrochloride within cutting-edge preclinical workflows and differentiates itself by bridging metabolic and osteoimmune domains, escalating the discourse beyond standard product summaries.

11167 records 2/745 page Previous Next 12345 下5页 Last page